Intensity Therapeutics is a clinical stage, biotechnology company whose mission is to create safer and more efficacious cancer therapies. Nasdaq: $INTS
Shelton, CT
Joined February 2013
- Tweets764
- Following258
- Followers955
- Likes352
Intensity Therapeutics retweeted
Last night, $INTS attended @Runway4Recovery's Runway Show NYC in support of #breastcancerawareness.
#INTS' CEO Lew Bender, joined Eve Bender, VP of sales at @FValentineNY, who dressed five models for the event.
An inspiring evening honoring those impacted.
#RunwayForRecovery
Intensity Therapeutics retweeted
About 350,000 women are diagnosed with breast cancer annually.
The Runway Show last night was a powerful celebration of 85 women who beat or are fighting #breastcancer, including my sister.
Intensity remains committed to developing a new drug that someday will help more BC patients live healthier, longer lives. - Lewis Bender
Intensity Therapeutics retweeted
$INTS reports 2025 year-end financial results and a corporate update.
$20M+ raised in 2025, with runway into Q2 2027. INT230-6 data published in @eBioMedicine.
Full release: bit.ly/4dNC67o
#FinancialResults
Intensity Therapeutics retweeted
#IntensityTherapeutics received a 180-day extension from @Nasdaq to regain compliance with the $1.00 minimum bid requirement.
There is no immediate impact on the Company’s listing, and $INTS will continue trading on the #Nasdaq Capital Market.
Full PR: bit.ly/4pkrD6i
Intensity Therapeutics retweeted
Tomorrow at 9 AM ET, $INTS will host a live webinar with authors from @uscnorris & CEO @LewBender on the @eBioMedicine study of INT230-6 in advanced solid tumors. Join to hear key insights from the Phase 1/2 trial.
Register: bit.ly/3Wu6ObT
#eBioMedicine @DrElkhoueiry
Intensity Therapeutics retweeted
OICR, Intensity Therapeutics and The Ottawa Hospital to conduct Window of Opportunity clinical trial in early-stage breast cancer ow.ly/FdW350E7bFd @IntensityInc @OttawaHospital
Intensity Therapeutics retweeted
Exciting news from Portage Biotech's subsidiary company @IntensityInc #FFWD
🔗read the full release: bit.ly/33078EC
Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study (IT-01/KEYNOTE A10) in Patients with Advanced Solid Tumors at SITC 2020 (Abstract 411) bit.ly/36mulB4
Intensity Therapeutics retweeted
☀️Wake up with our podcast!☕️
Lew Bender, founder of @IntensityInc discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors, this innovative process kills #tumors & shuts down #cancer cells.
🎙 bit.ly/2LF6enr
Intensity Therapeutics retweeted
Update from our investee company #Portage today
@IntensityInc has entered into a clinical collaboration with Bristol Myers Squibb, a global leader in immuno-oncology, to evaluate the potential of INT230-6 in combination with immunotherapy
👉bit.ly/3enI0ex
$FFWD #AIM
Intensity Therapeutics retweeted
Our client, Intensity Therapeutics, @IntensityInc , is changing the way cancer patients are treated. Learn more about their drug development journey in @EdClinical’s article in Clinical Leader bit.ly/33JGOgk
Intensity Therapeutics retweeted
Intensity Therapeutics CEO Lew Bender is featured on the BioBoss podcast in an interview conducted by John Simboli. Lew talks about #healthcare, #leadership and the promising results of Intensity’s unique method of treating #cancer. Listen at bit.ly/2QC5HVR
Intensity Therapeutics retweeted
Enjoyed my conversation with Lew. His passion for his work at Intensity and his vision for the future of cancer treatment are inspiring.
Intensity Therapeutics CEO Lew Bender is featured on the BioBoss podcast in an interview conducted by John Simboli. Lew talks about #healthcare, #leadership and the promising results of Intensity’s unique method of treating #cancer. Listen at bit.ly/2QC5HVR
Intensity Therapeutics retweeted
Now available—#BioBoss #podcast with Lewis Bender, #founder & #CEO #IntensityTherapeutics. Subscribe apple.co/2QCCcU2 et al. #cancer #Biotech #Biopharma #Intratumoral #CancerTherapy #Tumor #innovation @IntensityInc @DetailJunkie @Pharmaprodigy
@BioCT_org @CT_Innovate
Intensity Therapeutics retweeted
Check out this inspiring @Forbes feature about how our client, @IntensityInc. Lew Bender used his background in chemical engineering and drug development to invent an intratumoral #cancertreatment that is now in clinical trials bit.ly/2DkY7rS
Intensity Therapeutics retweeted
Intensity CEO Lew Bender is quoted in a new PharmaVOICE article with regards to how to obtain funding for young biotech company research. bit.ly/2XwwBRr
Intensity Therapeutics retweeted
Intensity is proud to announce we have treated our first patient with our drug INT230-6 in combination with Merck's Keytruda. We continue to seek to understand the effectiveness of our drug alone and in combination with other drugs in clinical trials. bwnews.pr/2NS1L1p
Intensity Therapeutics retweeted
Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Merck’s Keytruda® bwnews.pr/2JGqBjn
Intensity Therapeutics retweeted
2019 #PharmaVOICE100 Lewis Bender, CEO, Intensity Therapeutics invented a treatment to help the immune system identify cancer cells-with no experience in research or cancer. Start-in-the-basement story, he founded @IntensityInc in 2012. #pharma #leadership
pharmavoice.com/digital-edit…
Intensity Therapeutics retweeted
Intensity Therapeutics’ INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology. INT230-6 shows ability to regress tumors and initiate a T cell mediated systemic immune response against cancer.
bit.ly/2XUEoa7